Alnylam Pharmaceuticals
A biopharmaceutical company focusing on the discovery, development, and commercialization of RNAi therapeutics for treating rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS) diseases.
Seedtable Score
28
Startups
7
Funding Rounds
$886.1m
Money raised
Overview
Unlock Complete Company Intelligence
Access comprehensive data and insights available only to Seedtable members
Financial Details
- • Complete funding history and valuations
- • Revenue estimates and financial metrics
- • Investment round details and terms
People & Contacts
- • Complete leadership team profiles
- • Contact information and email addresses
- • Board members and advisors
Market Intelligence
- • Competitive landscape analysis
- • Market position and growth metrics
- • Industry benchmarking data
Premium Tools
- • Export data and generate reports
- • Save companies to custom watchlists
- • API access for data integration
Join 10,000+ Professionals
Trusted by investors, founders, and analysts worldwide
Access detailed insights on 71,000+ companies worldwide
| Name | Phone | Social networks | |
|---|---|---|---|
| Ph***** Sh*** | - | - | - |
| Ro**** La**** | - | - | - |
| Pa** Sc****** | - | - | - |
| Ph***** D. Za**** | - | - | - |
| Jo** Cl**** | - | - | - |
| Th**** Tu**** | - | - | - |
| Da*** Ba**** | - | - | - |
| Name | Phone | Social networks | |
|---|---|---|---|
| Mi***** W. Bo**** | - | - | - |
| De**** A. Au****** | - | - | - |
| Da*** E.** Py*** | - | - | - |
| Am* W. Sc****** | - | - | - |
| Ma**** H. Fa***** | - | - | - |
| Ol***** Br********* | - | - | - |
| YV**** GR********* | - | - | |
| Ma****** A. Ha***** | - | - | - |
Funding
Funding series
Funding Series Analysis
The company Alnylam Pharmaceuticals has raised a total of $886.1m in funding over 7 rounds.
Key Insights:
- Alnylam Pharmaceuticals Private equity, April 2020: $100m
- Alnylam Pharmaceuticals Private equity, April 2020: $750m
- Alnylam Pharmaceuticals Private equity, April 2019: $800k
- Alnylam Pharmaceuticals Private equity, January 2014: $700k
- Alnylam Pharmaceuticals funding round, March 2011: $10m
- Alnylam Pharmaceuticals Venture round, July 2003: $24.6m